Csenge Advisory Group bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 2,946 shares of the biotechnology company’s stock, valued at approximately $628,000.
Other hedge funds have also made changes to their positions in the company. Advisory Services Network LLC acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $26,000. Jones Financial Companies Lllp increased its position in Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 83 shares in the last quarter. Quadrant Capital Group LLC acquired a new stake in Ascendis Pharma A/S in the 3rd quarter valued at about $74,000. Farther Finance Advisors LLC increased its position in Ascendis Pharma A/S by 15.1% in the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 72 shares in the last quarter. Finally, Ninepoint Partners LP acquired a new stake in Ascendis Pharma A/S in the 3rd quarter valued at about $149,000.
Wall Street Analyst Weigh In
Several research firms have weighed in on ASND. Jefferies Financial Group began coverage on shares of Ascendis Pharma A/S in a research report on Monday, March 16th. They issued a “buy” rating and a $290.00 price objective for the company. Oppenheimer raised their price objective on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Wolfe Research restated an “outperform” rating and issued a $260.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Morgan Stanley restated an “overweight” rating and issued a $256.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday, February 12th. Finally, Evercore restated an “outperform” rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $295.39.
Ascendis Pharma A/S Trading Up 2.6%
ASND opened at $247.51 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $15.44 billion, a PE ratio of 28.55 and a beta of 0.41. Ascendis Pharma A/S has a 1-year low of $153.49 and a 1-year high of $250.74. The firm has a 50-day moving average price of $232.29 and a two-hundred day moving average price of $221.64.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. As a group, equities analysts anticipate that Ascendis Pharma A/S will post 12.19 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 40.00% of the company’s stock.
Ascendis Pharma A/S Profile
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
